Making tumour cells easier for T cells to recognise

By targeting biological processes inside tumour cells, researchers at Karolinska Institutet found ways to improve how effectively tumour cells were recognised by T cells in experimental models. The findings, presented in a doctoral thesis, suggest that altering tumour-cell mechanisms involved in immune evasion may improve recognition by T cells.
Immunotherapy has transformed cancer treatment, but not all patients experience long-term benefit, as tumour cells can develop ways of evading the immune system. In his doctoral thesis, Lucas Baldran-Groves at the Department of Oncology-Pathology investigated whether changes within tumour cells could improve their recognition by T cells, immune cells that can recognise and attack cancer cells.
The thesis examined three biological processes that may influence how effectively tumour cells are recognised by T cells. In the first study, blocking proteins known as BET proteins made melanoma cells easier for tumour-specific T cells to recognise. The second study showed that BET inhibition enhanced the tumour cells' response to antiviral signalling. When combined with activation of the cells antiviral defence system, this led to improved recognition by tumour-specific T cells.
The third study focused on PIKfyve, a protein involved in cellular recycling. Inhibiting PIKfyve made melanoma and sarcoma cells more susceptible to attack by T cells and was associated with reduced tumour spread in a mouse model of metastatic cancer.

"Much of cancer immunotherapy focuses on strengthening the immune response. In this thesis, we asked a different question: can we make tumour cells themselves easier for T cells to recognise and attack?" says Lucas Baldran-Groves.
Overall, the findings suggest that tumour-cell processes involved in gene regulation, antiviral signalling and cellular recycling can influence how effectively tumour cells are recognised by T cells.
The research was conducted in laboratory models, including patient-derived tumour cells and T cells, as well as a mouse model of metastatic cancer. Further studies are needed to determine whether the findings could contribute to future cancer treatments.
The thesis was supervised by PhD Jeroen Melief. The public defence took place on 23 October.